The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior.
I have a question about the book:
'CNS Clinical Trials - Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders'.
Fill in the form below.
We will respond as fast as possible.
We value your privacy
We use cookies to measure traffic, improve Boekstra and let Google tailor ads to your interests. You can keep using the site either way — even if you decline. More info
